Claire N. Harrison

TL;DR: This article reviews four major themes: the impact upon classification of these disorders considering a radical review of current terminology, the indications for cytoreductive therapy in which the key targets are to reduce thrombohemorrhagic complications, relieve disease-related symptoms, and minimize the risk of transformation to secondary myeloid malignancy, and current and future therapeutic options.

TL;DR: Ruxolitinib was shown to be more effective than BAT at reducing spleen volume in all patient subgroups regardless of gender, age, mutation status, IPSS risk category, baseline spleen size, MF subtype, or ruxolit inib starting dose.

TL;DR: Regardless of baseline iron status, treatment with ruxolitinib was associated with improvements in concentration problems, cognitive function, dizziness, fatigue, headaches, and inactivity, although improvements were generally greater among patients with baseline iron deficiency.

TL;DR: In this paper , the authors discuss clinical evidence and provide expert advice on statements related to the management of patients with hematological malignancies in the COVID-19 pandemic.